DOCSLIB.ORG

Summary-Based Methylome-Wide Association Analyses Suggest Potential Genetically Driven Epigenetic Heterogeneity of Alzheimer’S Disease Alireza Nazarian*, Anatoliy I

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Summary-Based Methylome-Wide Association Analyses Suggest Potential Genetically Driven Epigenetic Heterogeneity of Alzheimer’S Disease Alireza Nazarian*, Anatoliy I Summary-based methylome-wide association analyses suggest potential genetically driven epigenetic heterogeneity of Alzheimer’s disease Alireza Nazarian*, Anatoliy I. Yashin, and Alexander M. Kulminski* Biodemography of Aging Research Unit, Social Science Research Institute, Duke University, Durham, NC, USA *Corresponding Authors: Alireza Nazarian and Alexander M. Kulminski Duke University Social Science Research Institute Biodemography of Aging Research Unit Erwin Mill Building, 2024 W. Main St. Durham, NC 27705 Emails: [email protected] and [email protected] 1 Supporting Acknowledgment This research was supported by Grants No. P01AG043352, R01AG047310, and R01AG065477 from the National Institute on Aging. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This manuscript was prepared using limited access datasets obtained though dbGaP (accession numbers: phs000287.v5.p1 (CHS), phs000007.v28.p10 (FHS), phs000428.v2.p2 (HRS), and phs000168.v2.p2 (LOADFS) at https://www.ncbi.nlm.nih.gov/gap) and the University of Michigan. Phenotypic HRS data are available publicly and through restricted access from http://hrsonline.isr.umich.edu/index.php?p=data. The Cardiovascular Health Study (CHS) was supported by contracts HHSN268201200036C, HHSN268200800007C, N01-HC-85079, N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC-85084, N01-HC-85085, N01-HC-85086, N01-HC-35129, N01 HC-15103, N01 HC-55222, N01-HC- 75150, N01-HC-45133, and N01-HC-85239; grant numbers U01 HL080295 and U01 HL130014 from the National Heart, Lung, and Blood Institute (NHLBI), and R01 AG-023629 from the National Institute on Aging, with additional contribution from the National Institute of Neurological Disorders and Stroke. A full list of principal CHS investigators and institutions can be found at https://chs-nhlbi.org/pi. This manuscript was not prepared in collaboration with CHS investigators and does not necessarily reflect the opinions or views of CHS, or the NHLBI. Support for the genotyping through the CARe Study was provided by NHLBI Contract N01-HC-65226. Additional support for infrastructure was provided by HL105756 and additional genotyping among the African-American cohort was supported in part by HL085251. DNA handling and genotyping at Cedars-Sinai Medical Center was supported in part by National Center for Research Resources grant UL1RR033176, now at the National Center for Advancing Translational Technologies CTSI grant UL1TR000124; in addition to the National Institute of Diabetes and Digestive and Kidney Diseases grant DK063491 to the Southern California Diabetes Endocrinology Research Center. The Framingham Heart Study (FHS) is conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with Boston University (Contract No. N01-HC-25195 and HHSN268201500001I). This manuscript was not prepared in collaboration with investigators of the FHS and does not necessarily reflect the opinions or views of the FHS, Boston University, or NHLBI. Funding for SHARe Affymetrix genotyping was provided by NHLBI Contract N02-HL-64278. SHARe Illumina genotyping was provided under an agreement between Illumina and Boston University. Funding for CARe genotyping was provided by NHLBI Contract N01-HC-65226. Funding support for the Framingham Dementia dataset was provided by NIH/NIA grant R01 AG08122. Funding support for the Framingham Inflammatory Markers was provided by NIH grants R01 HL064753, R01 HL076784 and R01 AG028321. Funding support for the Framingham C-reactive Protein dataset was provided by NIH grants R01 HL064753, R01 HL076784 and R01 AG028321. Funding support for the Framingham Adiponectin dataset was provided by NIH/NHLBI grant R01-DK-080739. Funding support for the Framingham Interleukin-6 dataset was provided by NIH grants R01 HL064753, R01 HL076784 and R01 AG028321. The Health and Retirement Study (HRS) genetic data is sponsored by the Genetics Resource with HRS April 21, 2010, version G Page 5 of 7 National Institute on Aging (grant numbers U01AG009740, RC2AG036495, and RC4AG039029) and was conducted by the University of Michigan. This manuscript 2 was not prepared in collaboration with HRS investigators and does not necessarily reflect the opinions or views of HRS. Funding support for the Late Onset Alzheimer’s Disease Family Study (LOADFS) was provided through the Division of Neuroscience, NIA. The LOADFS includes a genome-wide association study funded as part of the Division of Neuroscience, NIA. Assistance with phenotype harmonization and genotype cleaning, as well as with general study coordination, was provided by Genetic Consortium for Late Onset Alzheimer’s Disease. This manuscript was not prepared in collaboration with LOADFS investigators and does not necessarily reflect the opinions or views of LOADFS. 3 Tables Table S1: Blood-based methylome-wide association results ProbeID Chr ProbePos Gene SNP Pos A1 Freq PGWAS PmQTL bSMR SESMR PSMR PHEIDI NHEIDI Current? Previous? Region? Plan 1: All Subjects cg20486877 6p22.1 29626704 GABBR1 rs12530421 29581666 C 0.072 2.11E-04 3.47E-66 -0.284 0.057 5.17E-07 5.21E-02 20 N N N cg12893697 11p15.5 970389 AP2A2 rs7395773 970503 C 0.481 1.34E-05 0 -0.168 0.031 6.64E-08 4.36E-01 20 S S S cg06064525 11p15.5 970664 AP2A2 rs7395773 970503 C 0.481 1.34E-05 0 -0.158 0.029 6.30E-08 5.10E-01 20 S S S cg05626073 11p15.5 971527 AP2A2 rs7395773 970503 C 0.481 1.34E-05 1.75E-305 -0.188 0.035 7.49E-08 1.25E-01 20 S S S cg09162537 11p15.5 976950 AP2A2 rs7395402 950293 C 0.447 1.54E-05 4.81E-59 -0.352 0.069 3.04E-07 2.03E-01 20 S S S cg21806090 12p13.33 2088868 CACNA1C rs56401832 2074725 C 0.030 2.28E-03 5.18E-165 -0.141 0.028 3.43E-07 3.63E-01 6 N N N cg00222015 12q24.31 121795469 LINC01089 rs7964357 121893222 C 0.025 3.21E-04 0 -0.130 0.021 1.54E-09 2.50E-01 20 N N N cg06750524 19q13.32 44906698 APOE rs769449 44906745 A 0.112 2.15E-83 9.38E-15 3.617 0.469 1.24E-14 9.03E-02 10 G G G Plan 2: Only Males cg20011360 4p14 37584038 C4orf19 rs2276944 37584048 A 0.106 5.94E-04 3.40E-180 0.366 0.058 2.62E-10 3.04E-01 17 N N N cg23395749 5q35.3 177557245 IGR (FAM193B) rs1001530 177558514 G 0.046 4.38E-03 2.55E-26 -0.559 0.109 2.95E-07 2.48E-01 5 N S S cg04627871 6p21.33 31736144 CLIC1 rs34585796 31778065 T 0.013 2.46E-02 2.57E-54 0.339 0.059 1.09E-08 1.24E-01 10 N G S cg15598276 6p21.32 32980566 BRD2 rs115417321 32973918 C 0.016 6.96E-03 9.03E-38 -0.484 0.073 2.68E-11 2.61E-01 14 N G G cg01991743 6p21.32 33085831 HLA-DPB1 rs11551421 33085832 A 0.039 1.59E-03 0 -0.140 0.025 2.79E-08 2.29E-01 20 N G G cg06527438 6q27 170236746 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 1.44E-25 -0.548 0.098 2.10E-08 4.10E-01 5 N N S cg21205282 6q27 170244045 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 2.90E-16 -0.693 0.134 2.55E-07 8.05E-02 5 N N S cg22883453 6q27 170244276 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 1.09E-19 -0.628 0.117 8.38E-08 5.52E-02 4 N N S cg04505845 6q27 170244461 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 7.99E-22 -0.592 0.108 4.76E-08 2.03E-01 4 N N S cg05526015 6q27 170244757 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 1.13E-35 -0.463 0.079 4.65E-09 2.18E-01 6 N N S cg24651908 6q27 170245433 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 1.52E-18 -0.650 0.123 1.18E-07 5.85E-02 4 N N S cg04386759 6q27 170245707 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 1.36E-25 -0.542 0.097 2.09E-08 5.91E-02 5 N N S cg26180843 6q27 170248014 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 1.75E-21 -0.584 0.107 5.18E-08 1.14E-01 5 N N S cg12035402 6q27 170250189 IGR (LOC154449) rs58691983 170238096 A 0.013 2.95E-02 1.02E-16 -0.692 0.133 2.16E-07 7.79E-02 5 N N S cg05438220 7q21.13 90643046 CDK14 rs17864073 90601202 A 0.022 6.89E-03 0 -0.125 0.023 3.54E-08 2.11E-01 15 N N S cg11399834 8p22 14566901 SGCZ rs7013654 14587192 T 0.047 1.75E-03 6.43E-156 -0.348 0.054 1.20E-10 2.06E-01 20 N N G cg12185975 8q24.22 130761450 IGR (ADCY8) rs79599781 130735526 A 0.057 5.42E-04 2.13E-165 -0.239 0.040 1.73E-09 6.17E-01 20 S S S cg23402755 10p14 7702004 ITIH2 rs76129783 7716283 C 0.027 2.98E-03 1.29E-26 -0.453 0.089 3.85E-07 6.42E-01 12 N G G cg14381908 10q11.21 43202369 RASGEF1A rs35718664 43158746 G 0.056 2.03E-03 1.22E-195 0.204 0.040 4.90E-07 2.63E-01 18 N N N cg25422051 11q13.1 65916842 C11orf68 rs7940700 65903526 T 0.015 2.87E-02 5.91E-26 -0.658 0.094 2.43E-12 3.54E-01 7 N N N cg15007809 12q21.2 75883289 IGR (PHLDA1) rs11180729 75883290 A 0.014 1.08E-02 1.65E-298 -0.190 0.021 8.73E-20 4.99E-01 10 N G G cg19755435 14q31.3 88006657 GPR65 rs1372363 88006834 T 0.076 8.12E-04 2.90E-45 -0.462 0.087 1.04E-07 3.79E-01 20 N N S cg20239174 15q24.1 73780023 IGR (C15orf59) rs1869176 73789242 T 0.010 4.71E-02 3.59E-224 -0.160 0.025 2.42E-10 5.18E-01 7 N N N cg24801087 17q25.3 78485647 DNAH17,DNAH17-AS1 rs654154 78485428 C 0.061 3.39E-03 2.53E-45 -0.573 0.106 6.81E-08 2.09E-01 13 N S S cg08778119 17q25.3 78496484 DNAH17,DNAH17-AS1 rs12944401 78611646 T 0.028 3.54E-03 5.02E-40 -0.483 0.087 3.23E-08 3.68E-01 4 N S S cg06750524 19q13.32 44906698 APOE rs769449 44906745 A 0.112 7.08E-30 9.38E-15 3.651 0.477 1.92E-14 1.39E-01 10 G G G cg05206559 19q13.32 45913997 NANOS2 rs66529687 45914171 A 0.133 1.83E-04 2.84E-41 0.723 0.125 7.67E-09 3.28E-01 20 G G G cg25673584 19q13.32 45914293 NANOS2 rs66529687 45914171 A 0.133
Load more

Recommended publications
  • A Sex-Stratified Genome-Wide Association Study of Tuberculosis Using a Multi-Ethnic Genotyping Array
    UC Davis UC Davis Previously Published Works Title A Sex-Stratified Genome-Wide Association Study of Tuberculosis Using a Multi-Ethnic Genotyping Array. Permalink https://escholarship.org/uc/item/0pk953bj Journal Frontiers in genetics, 9(JAN) ISSN 1664-8021 Authors Schurz, Haiko Kinnear, Craig J Gignoux, Chris et al. Publication Date 2018 DOI 10.3389/fgene.2018.00678 Peer reviewed eScholarship.org Powered by the California Digital Library University of California fgene-09-00678 January 16, 2019 Time: 18:45 # 1 ORIGINAL RESEARCH published: 18 January 2019 doi: 10.3389/fgene.2018.00678 A Sex-Stratified Genome-Wide Association Study of Tuberculosis Using a Multi-Ethnic Genotyping Array Haiko Schurz1,2*, Craig J. Kinnear1, Chris Gignoux3, Genevieve Wojcik4, Paul D. van Helden1, Gerard Tromp1,2,5, Brenna Henn6, Eileen G. Hoal1 and Marlo Möller1 1 DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, 2 South African Tuberculosis Bioinformatics Initiative, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa, 3 Colorado Center for Personalized Medicine, Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, 4 Department of Genetics, Stanford University, Stanford, CA, United States, 5 Centre for Bioinformatics and Computational Biology, Stellenbosch University, Cape Town, South Africa, 6 Department of Anthropology, UC Davis Genome Center, University of California, Davis, Davis, CA, United States Edited by: Zané Lombard, University of the Witwatersrand, Tuberculosis (TB), caused by Mycobacterium tuberculosis, is a complex disease with a South Africa known human genetic component.
    [Show full text]
  • Arnau Soler2019.Pdf
    This thesis has been submitted in fulfilment of the requirements for a postgraduate degree (e.g. PhD, MPhil, DClinPsychol) at the University of Edinburgh. Please note the following terms and conditions of use: This work is protected by copyright and other intellectual property rights, which are retained by the thesis author, unless otherwise stated. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This thesis cannot be reproduced or quoted extensively from without first obtaining permission in writing from the author. The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the author. When referring to this work, full bibliographic details including the author, title, awarding institution and date of the thesis must be given. Genetic responses to environmental stress underlying major depressive disorder Aleix Arnau Soler Doctor of Philosophy The University of Edinburgh 2019 Declaration I hereby declare that this thesis has been composed by myself and that the work presented within has not been submitted for any other degree or professional qualification. I confirm that the work submitted is my own, except where work which has formed part of jointly-authored publications has been included. My contribution and those of the other authors to this work are indicated below. I confirm that appropriate credit has been given within this thesis where reference has been made to the work of others. I composed this thesis under guidance of Dr. Pippa Thomson. Chapter 2 has been published in PLOS ONE and is attached in the Appendix A, chapter 4 and chapter 5 are published in Translational Psychiatry and are attached in the Appendix C and D, and I expect to submit chapter 6 as a manuscript for publication.
    [Show full text]
  • <Abstract Centered> an ABSTRACT of the THESIS OF
    AN ABSTRACT OF THE DISSERTATION OF Michael Austin Garland for the degree of Doctor of Philosophy in Toxicology presented on June 14, 2019. Title: Transcriptomic Approaches for Discovering Regenerative and Developmental Regulatory Networks in Zebrafish Abstract approved: _____________________________________________________________________ Robert L. Tanguay Zebrafish are capable of fully regenerating organs and tissue such as their caudal fin, which is similar to a human regrowing an arm or a leg. In contrast, most mammals including humans have a greatly reduced capacity for wound healing. The ability of zebrafish to undergo this regenerative process, called epimorphic regeneration, hinges on the capacity to form a blastema at the wound site. The blastema quickly recapitulates the developmental processes involved in complex tissue formation to restore lost or damaged tissue. One key mechanism for inducing blastema formation is global repression of genes involved in tissue differentiation and maintenance. Induction of repressive factors, such as microRNAs (miRNAs), are involved in reprogramming cells during epimorphic regeneration. The upstream mechanism by which zebrafish undergo epimorphic regeneration remains elusive. Furthermore, while focus is shifting toward regulatory RNAs such as miRNAs, the full complement of their repressive activities is unknown. We took a transcriptomics approach to investigating epimorphic regeneration and fin development. Parallel sequencing of total RNA and small RNA samples was performed on regenerating fin tissue at 1 day post-amputation (dpa). Most miRNAs had increased expression, consistent with global repression of genes involved in cell specialization during de-differentiation. We identified predicted interactions between miRNAs and genes involved in transcriptional regulation, chromatin modification, and developmental signaling. miR-146a and miR-146b are anti- inflammatory miRNAs that were predicted to target eya4, which is involved in chromatin remodeling and innate immunity.
    [Show full text]
  • PRODUCTS and SERVICES Target List
    PRODUCTS AND SERVICES Target list Kinase Products P.1-11 Kinase Products Biochemical Assays P.12 "QuickScout Screening Assist™ Kits" Kinase Protein Assay Kits P.13 "QuickScout Custom Profiling & Panel Profiling Series" Targets P.14 "QuickScout Custom Profiling Series" Preincubation Targets Cell-Based Assays P.15 NanoBRET™ TE Intracellular Kinase Cell-Based Assay Service Targets P.16 Tyrosine Kinase Ba/F3 Cell-Based Assay Service Targets P.17 Kinase HEK293 Cell-Based Assay Service ～ClariCELL™ ～ Targets P.18 Detection of Protein-Protein Interactions ～ProbeX™～ Stable Cell Lines Crystallization Services P.19 FastLane™ Structures ～Premium～ P.20-21 FastLane™ Structures ～Standard～ Kinase Products For details of products, please see "PRODUCTS AND SERVICES" on page 1～3. Tyrosine Kinases Note: Please contact us for availability or further information. Information may be changed without notice. Expression Protein Kinase Tag Carna Product Name Catalog No. Construct Sequence Accession Number Tag Location System HIS ABL(ABL1) 08-001 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) BTN BTN-ABL(ABL1) 08-401-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ABL(ABL1) [E255K] HIS ABL(ABL1)[E255K] 08-094 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) HIS ABL(ABL1)[T315I] 08-093 Full-length 2-1130 NP_005148.2 N-terminal His Insect (sf21) ABL(ABL1) [T315I] BTN BTN-ABL(ABL1)[T315I] 08-493-20N Full-length 2-1130 NP_005148.2 N-terminal DYKDDDDK Insect (sf21) ACK(TNK2) GST ACK(TNK2) 08-196 Catalytic domain
    [Show full text]
  • Page 1 Exploring the Understudied Human Kinome For
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.02.022277; this version posted June 30, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Exploring the understudied human kinome for research and therapeutic opportunities Nienke Moret1,2,*, Changchang Liu1,2,*, Benjamin M. Gyori2, John A. Bachman,2, Albert Steppi2, Rahil Taujale3, Liang-Chin Huang3, Clemens Hug2, Matt Berginski1,4,5, Shawn Gomez1,4,5, Natarajan Kannan,1,3 and Peter K. Sorger1,2,† *These authors contributed equally † Corresponding author 1The NIH Understudied Kinome Consortium 2Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts 02115, USA 3 Institute of Bioinformatics, University of Georgia, Athens, GA, 30602 USA 4 Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA 5 Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC 27599, USA Key Words: kinase, human kinome, kinase inhibitors, drug discovery, cancer, cheminformatics, † Peter Sorger Warren Alpert 432 200 Longwood Avenue Harvard Medical School, Boston MA 02115 [email protected] cc: [email protected] 617-432-6901 ORCID Numbers Peter K. Sorger 0000-0002-3364-1838 Nienke Moret 0000-0001-6038-6863 Changchang Liu 0000-0003-4594-4577 Ben Gyori 0000-0001-9439-5346 John Bachman 0000-0001-6095-2466 Albert Steppi 0000-0001-5871-6245 Page 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.02.022277; this version posted June 30, 2020.
    [Show full text]
  • Biomarkers and Genetics of Canine Visceral Haemangiosarcoma
    Biomarkers and genetics of canine visceral haemangiosarcoma Patharee Oungsakul Doctor of Veterinary Medicine, Master of Veterinary Studies 0000-0003-4523-3484 A thesis submitted for the degree of Doctor of Philosophy at The University of Queensland in Year 2020 School of Veterinary Science Abstract Visceral haemangiosarcoma (HSA) is a vascular endothelial cell cancer that arises in internal organs, especially in the spleen. HSA carries a very poor prognosis but is also difficult to diagnose. Therefore, dogs with HSA symptoms are often euthanized without full investigation. The goal of the thesis was to improve the diagnosis and prevention of this cancer by exploring several HSA biomarkers. The thesis comprises four independent biomarker studies regarding glycoproteins, genetics and Infrared spectral markers. The aim of the first study (chapter 2) was to validate the candidates for canine visceral HSA serum biomarkers, by performing tissue immuno- and lectin-labelling of HSA (n = 32) and HSA-like (n=26) formalin-fixed paraffin-embedded (FFPE) tissues with C7 (component complement 7), MGAM (maltase-glucoamylase), VTN (vitronectin) antibodies and DSA (Datura stramonium), WGA (Wheat germ agglutinin), SNA (Sambucus nigra) and PSA (Pisum sativum)lectins. The results showed lectin/immuno-positive signal on HSA cells, endothelial cell of the veins and arteries. IHC and LHC signal intensities were heterogeneous across the tissue types, diagnosis groups (HSA vs HSA-like) and tissue markers. A semi-quantitative assay was applied to assess and compare the levels of IHC/LHC signal intensities of each marker. Among the candidates tested, complement component 7 (C7) and DSA binding glycoproteins were considered the most promising tissue markers as they demonstrated the ability to distinguish HSA tissue from HSA-like tissues (e.g.
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • A Resource for Exploring the Understudied Human Kinome for Research and Therapeutic
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.02.022277; this version posted March 11, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. A resource for exploring the understudied human kinome for research and therapeutic opportunities Nienke Moret1,2,*, Changchang Liu1,2,*, Benjamin M. Gyori2, John A. Bachman,2, Albert Steppi2, Clemens Hug2, Rahil Taujale3, Liang-Chin Huang3, Matthew E. Berginski1,4,5, Shawn M. Gomez1,4,5, Natarajan Kannan,1,3 and Peter K. Sorger1,2,† *These authors contributed equally † Corresponding author 1The NIH Understudied Kinome Consortium 2Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Program in Therapeutic Science, Harvard Medical School, Boston, Massachusetts 02115, USA 3 Institute of Bioinformatics, University of Georgia, Athens, GA, 30602 USA 4 Department of Pharmacology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA 5 Joint Department of Biomedical Engineering at the University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, NC 27599, USA † Peter Sorger Warren Alpert 432 200 Longwood Avenue Harvard Medical School, Boston MA 02115 [email protected] cc: [email protected] 617-432-6901 ORCID Numbers Peter K. Sorger 0000-0002-3364-1838 Nienke Moret 0000-0001-6038-6863 Changchang Liu 0000-0003-4594-4577 Benjamin M. Gyori 0000-0001-9439-5346 John A. Bachman 0000-0001-6095-2466 Albert Steppi 0000-0001-5871-6245 Shawn M.
    [Show full text]
  • The Cancer Genome Atlas Dataset-Based Analysis of Aberrantly Expressed Genes by Geneanalytics in Thymoma Associated Myasthenia Gravis: Focusing on T Cells
    2323 Original Article The Cancer Genome Atlas dataset-based analysis of aberrantly expressed genes by GeneAnalytics in thymoma associated myasthenia gravis: focusing on T cells Jianying Xi1#, Liang Wang1#, Chong Yan1, Jie Song1, Yang Song2, Ji Chen2, Yongjun Zhu2, Zhiming Chen2, Chun Jin3, Jianyong Ding3, Chongbo Zhao1,4 1Department of Neurology, 2Department of Thoracic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China; 3Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai 200030, China; 4Department of Neurology, Jing’an District Centre Hospital of Shanghai, Fudan University, Shanghai 200040, China Contributions: (I) Conception and design: J Xi, L Wang, C Zhao; (II) Administrative support: J Xi, L Wang, C Zhao; (III) Provision of study materials or patients: Y Song, Y Zhu, J Chen, Z Chen, C Jin, J Ding; (IV) Collection and assembly of data: C Jin, J Ding; (V) Data analysis and interpretation: C Yan, J Song; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. #These authors contributed equally to this work. Correspondence to: Chongbo Zhao. Department of Neurology, Huashan Hospital, Fudan University, Shanghai 200040, China. Email: [email protected]. Background: Myasthenia gravis (MG) is a group of autoimmune disease which could be accompanied by thymoma. Many differences have been observed between thymoma-associated MG (TAMG) and non-MG thymoma (NMG). However, the molecular difference between them remained unknown. This study aimed to explore the differentially expressed genes (DEGs) between the two categories and to elucidate the possible pathogenesis of TAMG further. Methods: DEGs were calculated using the RNA-Sequencing data from 11 TAMG and 10 NMG in The Cancer Genome Atlas (TCGA) database.
    [Show full text]
  • Supplemental Figure 1
    A BCD6 35 80 1.0 3 Thr Ala 0.4 Thr Ala 30 0.8 60 4 0.3 2 25 0.6 40 20 0.2 0.4 1 2 20 intake(g)Food Body weight(g) 15 0.1 0.2 Serum TSH (ng/ml) T4 plasmaT4 levels (ng/ml) plasma levelsT3 (ng/ml) 1/V 10 0.0 0 0.0 0 5 10 15 Thr Ala Thr Ala Thr Ala -1.0 -0.5 0.5 1.0 1.5 2.0 Thr Ala Thr Ala Age (weeks) 1/[T4] (nM) dark light (fmols/min/mg ptn) (fmols/min/mg -1 Ala Thr IKMN O Femur 16.5 0.55 1100 0.24 E F 16.0 1050 0.22 G H 0.50 Thr92‐D2 15.5 1000 0.20 Ala92‐D2 0.45 15.0 950 0.18 (mgHAcm-3) Femur volume 0.40 14.5 900 0.16 Cortical thickness Femur length (mm) length Femur Bone MineralDensity 14.0 0.35 850 0.14 Thr Ala Thr Ala Thr Ala Thr Ala JLPQR Vertebrae 4.6 5.5 0.070 0.35 4.4 5.0 0.065 0.30 **P<0.01 0.060 4.2 *** 4.5 0.055 0.25 4.0 4.0 0.050 0.20 3.8 3.5 Trabecular number 0.045 Trabecular spacing Trabecular thickness Vertebral height (mm) height Vertebral 3.6 3.0 0.040 0.15 Thr Ala Thr Ala Thr Ala Thr Ala Figure S1: Additional phenotype of the Ala92‐Dio2 mouse.
    [Show full text]
  • Identification of Potential and Novel Target Genes in Pituitary Prolactinoma by Bioinformatics Analysis
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423732; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Identification of potential and novel target genes in pituitary prolactinoma by bioinformatics analysis 1 2 3 4* Vikrant Ghatnatti , Basavaraj Vastrad , Swetha Patil , Chanabasayya Vastrad , Iranna Kotturshetti5 1. Dept of Endocrinology/Medicine, J N Medical College, Belagavi 590010, Karnataka, India. 2. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 3. Dept of Obstetrics and Gynaecology, J N Medical college, Belagavi 590010, Karnataka, India. 4. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India. 5. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron 562209, Karanataka, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India Abstract bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423732; this version posted December 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Pituitary prolactinoma is one of the most complicated and fatally pathogenic pituitary adenomas. Therefore, there is an urgent need to improve our understanding of the underlying molecular mechanism that drives the initiation, progression, and metastasis of pituitary prolactinoma. The aim of the present study was to identify the key genes and signaling pathways associated with pituitary prolactinoma using bioinformatics analysis. Transcriptome microarray dataset GSE119063 was acquired from Gene Expression Omnibus datasets, which included 5 pituitary prolactinoma samples and 4 normal pituitaries samples.
    [Show full text]
  • Supplementary Material
    Supplementary Material Table of Contents Figure S1 ................................................................................................................................................................................... 2 Figure S2 ................................................................................................................................................................................... 3 Figure S3 ................................................................................................................................................................................... 4 Table S1. 225 Autophagy Modulators. .................................................................................................................................... 5 Table S2. 993 known targets and 12 predicted targets of autophagy modulators ................................................................. 9 Table S3. 368 Predicted ATG interactions and experimental validation ............................................................................ 33 Table S4. GO annotation enrichments based on ATG targets.............................................................................................. 39 Table S5. Pathways enriched in targets of autophagy modulators, corresponding targets, and autophagy modulators . 42 Supplementary References ................................................................................................................................................... 65 1 Figure S1. Distribution of the
    [Show full text]